Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Prepaid Assets: 2019-2024

Historic Prepaid Assets for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $34.9 million.

  • BridgeBio Pharma's Prepaid Assets rose 36.56% to $52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year increase of 36.56%. This contributed to the annual value of $34.9 million for FY2024, which is 43.46% up from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Prepaid Assets is $34.9 million, which was up 43.46% from $24.3 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Prepaid Assets registered a high of $35.7 million during FY2020, and its lowest value of $21.9 million during FY2022.
  • For the 3-year period, BridgeBio Pharma's Prepaid Assets averaged around $27.0 million, with its median value being $24.3 million (2023).
  • In the last 5 years, BridgeBio Pharma's Prepaid Assets skyrocketed by 80.61% in 2020 and then tumbled by 32.06% in 2022.
  • BridgeBio Pharma's Prepaid Assets (Yearly) stood at $35.7 million in 2020, then declined by 9.69% to $32.3 million in 2021, then tumbled by 32.06% to $21.9 million in 2022, then increased by 10.87% to $24.3 million in 2023, then surged by 43.46% to $34.9 million in 2024.